Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity

NCT ID: NCT01386073

Last Updated: 2012-06-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-07-31

Study Completion Date

2012-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the efficacy of FreshKote and Systane for the reduction of dry eye signs and symptoms.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dry Eye

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FreshKote

Group Type ACTIVE_COMPARATOR

FreshKote

Intervention Type DRUG

Three times a day for three months

Systane

Group Type PLACEBO_COMPARATOR

Systane

Intervention Type DRUG

three times a day for three months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FreshKote

Three times a day for three months

Intervention Type DRUG

Systane

three times a day for three months

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Dry eye patients with Level 2 disease or greater as defined by the Delpi Panel
* Tear osmolarity of at least 308 mosm
* At least 18 years of age, Male or Female
* Willing to provide written informed consent
* Likely to complete all study visits
* If currently using ocular lubricants, must complete a 10-14 day washout

Exclusion Criteria

* Presence of any active ocular disease other than dry eye
* Use of topical ophthalmic medications
* Use of contact lenses during the trial
* Pregnant or nursing, or planning a pregnancy. Patients will be asked if they are pregnant or may be pregnant and excluded if they answer in the affirmative.
* Any known sensitivity to any ingredients of either study drop
* Oral anti-inflammatory medications, omega 3 supplements, or doxycycline
* Punctal plugs inserted within the last 6 months or less
* Uncontrolled systemic disease
* Subjects with known sensitivity or inappropriate responsiveness to any of the medications used.
* Acute or chronic disease or illness that would increase risk or confound study results (e.g., uncontrolled diabetes mellitus, immunocompromised, etc.)
* Corneal abnormalities (e.g., ecstatic diseases, degenerations, or corneal dystrophies of the stroma or endothelium)
* Concurrent participation or participation in the last 30 days in any other clinical trial
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Innovative Medical

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

CRO

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jay Pepose, MD

Role: PRINCIPAL_INVESTIGATOR

Pepose Vision Institute

Mitch Jackson, MD

Role: PRINCIPAL_INVESTIGATOR

Jackson Eye, S.C

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Jackson Eye, S.C

Lake Villa, Illinois, United States

Site Status RECRUITING

Pepose Vision Institute

Chesterfield, Missouri, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jenna Piel

Role: CONTACT

951-653-5566

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jenna Piel

Role: primary

951-653-5566

Jenna Piel

Role: primary

951-653-5566

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Focus2011-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.